STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Want to see DE:SBS full AI Analyst Report?
Earnings Data
Report Date
Aug 14, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
0.09Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: Q1 showed material near-term weakness driven by an unfavorable product mix, lower high‑margin consumables and negative scaling effects that compressed margins. Offsetting this were strong cash generation (EUR 18.6m free cash flow), improved leverage, double-digit instrument growth, confirmed annual guidance (H2 weighted) and clear medium/long-term growth and margin targets. Key near-term risks remain the timing/firmness of consumables orders and elevated inventories/obsolescence. Overall the positives and negatives are balanced.Company Guidance
Revenue Reported for Q1 2026
Revenue of EUR 53.4 million in Q1 2026 (company stated figure).
Strong Cash Generation and Improved Free Cash Flow
Operating cash flow of EUR 21.5 million and free cash flow of EUR 18.6 million, described as a significant improvement versus the same quarter last year due to a reduction in trade receivables.
Leverage and Balance Sheet Improvement
Net financial debt decreased versus prior-year and leverage (net debt / EBITDA LTM) improved to 3.1x from 3.3x at end-2025.
Systems / Instrument Business Momentum
Systems/instrument business shows ongoing positive trend with double-digit growth in the quarter, indicating stable demand and positioning for future service & consumables revenue.
Guidance Confirmed and Long-Term Targets
Company confirmed 2026 guidance: medium to high single-digit top-line growth (constant currency) with H2 loading; EBIT guidance at 2025 level (~10%). Long-term targets: 6%-8% CAGR (2025–2028) and EBIT margin targets of ≥13% by 2028 and ~15% by 2030.
Capital Discipline and Investment Guidance
Combined investments (tangible + intangible) guided to 6.5%–8.5% of revenue; current capex ratio at 5.4% of revenue (slightly below planned range) reflecting cautious/phased investment approach.
Order/Forecast Visibility Improvements
Shift of some customers from rolling forecasts to firmer order patterns (especially for year-end business) increases transparency and supports more plannable H2 manufacturing and logistics.
DE:SBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:SBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | €17.70 | €17.60 | -0.56% |
Apr 28, 2026 | €18.58 | €18.00 | -3.12% |
Nov 07, 2025 | €20.65 | €19.64 | -4.89% |
Aug 19, 2025 | €25.85 | €27.00 | +4.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does STRATEC Biomedical AG (DE:SBS) report earnings?
STRATEC Biomedical AG (DE:SBS) is schdueled to report earning on Aug 14, 2026, Before Open (Confirmed).
What is STRATEC Biomedical AG (DE:SBS) earnings time?
STRATEC Biomedical AG (DE:SBS) earnings time is at Aug 14, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of STRATEC Biomedical AG stock?
The P/E ratio of STRATEC Biomedical is N/A.
What is DE:SBS EPS forecast?
DE:SBS EPS forecast for the fiscal quarter 2026 (Q2) is 0.24.